ipilimumab

• 

Nivolumab plus ipilimumab and live bacteria supplements in advanced kidney cancer

By Sharon Deveson Kell|2022-03-25T09:17:25+00:0025 Mar 2022|Drug treatments|

Researchers are interested in the bacteria in our gut (the [...]

Read More

Comments Off on Nivolumab plus ipilimumab and live bacteria supplements in advanced kidney cancer

• 

Ipilimumab plus nivolumab combination approved for use on the NHS

By Sharon Deveson Kell|2022-02-04T14:54:26+00:004 Feb 2022|Drug treatments|

The National Institute for Health and Care Excellence (NICE) has [...]

Read More

Comments Off on Ipilimumab plus nivolumab combination approved for use on the NHS

• 

First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy

By Sharon Deveson Kell|2021-11-26T08:30:27+00:0026 Nov 2021|Drug treatments|

A recent post hoc analysis of the CheckMate 214 trial [...]

Read More

Comments Off on First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy

• 

Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients

By Sharon Deveson Kell|2021-10-27T08:36:33+00:0027 Oct 2021|Drug treatments|

A recent study published in Journal of Clinical Medicine this [...]

Read More

Comments Off on Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients

• 

ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

By Sharon Deveson Kell|2021-09-23T07:53:58+00:0023 Sep 2021|Drug treatments|

The use of two medicines together (combination therapies) for previously [...]

Read More

Comments Off on ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

• 

ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

By Sharon Deveson Kell|2021-09-21T07:54:24+00:0021 Sep 2021|Drug treatments|

Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]

Read More

Comments Off on ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

• 

ASCO 2021: Gut microbiome boosts nivolumab/ipilimumab activity

By Robert|2021-07-07T13:03:09+00:0028 Jun 2021|Drug treatments|

Recent evidence suggests that the bacteria in the gut (the [...]

Read More

Comments Off on ASCO 2021: Gut microbiome boosts nivolumab/ipilimumab activity

• 

ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases

By Robert|2021-07-07T12:52:09+00:008 Jun 2021|Drug treatments|

Brain metastases resulting from the spread of renal cell carcinoma [...]

Read More

Comments Off on ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases

• 

ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

By Sharon Kell|2021-02-12T10:16:05+00:0012 Feb 2021|Drug treatments|

Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]

Read More

Comments Off on ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

• 

ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer

By Sharon Kell|2021-02-12T10:08:34+00:0012 Feb 2021|Drug treatments|

Data from the CheckMate-920 study on the safety and effectiveness [...]

Read More

Comments Off on ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer